Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01084174
Other study ID # NA_00032256
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received March 8, 2010
Last updated March 28, 2016
Start date March 2010
Est. completion date January 2013

Study information

Verified date March 2016
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.


Description:

To effectively address the Primary Objectives of this pilot study, 30 subjects aged 6-21 years with: (1) a convincing clinical history of PA, (2) a serum IgE specific to peanut of >0.35 kUa/L and a skin prick test (SPT) wheal >3 mm, will be enrolled. Subjects will be recruited from the Johns Hopkins Pediatric Allergy Clinic.

Participants will undergo an initial screening visit that will include a medical history, physical exam, skin testing, and phlebotomy. Informed consent and assent will be obtained. At the next two visits, 20 participants will complete a double-blind placebo-controlled food challenge (DBPCFC). Eligible subjects will be randomized in a 1:1 ratio into two groups. One group will receive active SLIT with placebo OIT and the other group will begin active OIT with placebo SLIT dose escalation. Over the next 16 weeks of the study, subjects will undergo SLIT and OIT dose increases. A maintenance dose will then be taken at home daily for 12 months. A DBPCFC will be completed after 6 months and 12 months of home dosing. Those patients who pass the DBPCFC will be taken off SLIT and OIT for 4 weeks. A final challenge will be administered at the end of this period.

Ten additional peanut-allergic subjects age 6-21 years will be enrolled and followed as longitudinal controls for the mechanistic studies. These subjects will follow a modified schedule compared to those subjects receiving study treatment and will be evaluated by phlebotomy, end point titration prick skin testing, and saliva collection. These patients will continue strict avoidance of peanut unless otherwise advised by their personal physician.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date January 2013
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 21 Years
Eligibility Inclusion Criteria:

- Are ages 6 to 21 years of either sex, any race, and any ethnicity at the time of the initial visit.

- Have a physician diagnosed peanut allergy or a convincing clinical history of peanut allergy (urticaria, upper or lower respiratory symptoms, GI disturbances, rash or oral symptoms).

- Have a skin prick test positive to peanut (diameter of wheal 3 mm = negative control) and detectable serum peanut-specific IgE level (UniCAP = 0.35 kUa/L).

- Have a positive reaction to a cumulative dose of =1,000 mg of peanut powder in the initial qualifying DBPCFC.

- Use an effective method of contraception by females of childbearing potential to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.

- Ability to perform spirometry maneuvers in accordance with the American Thoracic Society (ATS) guidelines (1994).

- Have self-injectable epinephrine (i.e. EpiPen® or EpiPen Jr.®) available at all times.

- Provide signed informed consent (by parent or legal guardian if the subject is a minor) and informed assent if applicable.

Exclusion Criteria:

- Have a history of severe anaphylaxis to peanut with hypoxia (cyanosis or SpO2 =92% at any stage), hypotension or neurological compromise (confusion, collapse, loss of consciousness or incontinence).

- Tolerates more than 1,000 mg of peanut powder at the initial qualifying DBPCFC.

- Have a viral URI or gastroenteritis within 7 days of OFC (OFC will need to be rescheduled).

- Currently participating in a study using an investigational new drug.

- Participation in any interventional study for the treatment of food allergy in the past 12 months.

- Pregnancy or lactation

- Allergy to placebo ingredients (Glycerin or oat flour) OR reacts to any dose of placebo during the qualifying OFC.

- Currently in a buildup phase of any allergy immunotherapy.

- Poor control of atopic dermatitis.

- Have pulmonary function tests with FEV1 value <80% predicted or any clinical features of greater than moderate persistent asthma and greater than high daily doses of inhaled corticosteroids (>500µg/day fluticasone or equivalent).

- Use of steroid medications (oral steroids, such as prednisone or Medrol, steroid injections, such as Kenalog, or IV or oral corticosteroid burst) in the following manners:

o History of daily oral steroid dosing within 4 weeks prior to baseline visit or for > 1 month during the past year or burst oral steroid course in the past 6 months or > 1 burst oral steroid course in the past year.

- Asthma requiring

- =1 hospitalization in the past year for asthma or

- >1 ER visit in the past 6 months for asthma

- Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immuno-modulatory therapy (not including corticosteroids) or biologic therapy within the past year.

- Use of ß-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB), calcium channel blockers or tricylic antidepressant therapy.

- Inability to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or OFC's.

- History of alcohol or drug abuse.

- Active eosinophilic gastrointestinal disease in the past two years.

- Have other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders) which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions.

- Any previous intubation due to allergies or asthma.

- Severe reaction at initial DBPCFC, defined as:

- Life-threatening anaphylaxis

- Requiring overnight hospitalization

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Peanut powder
Delivered orally
Peanut extract
Delivered sublingually
Placebo extract
Delivered sublingually
Placebo powder
Delivered orally

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is to determine if sublingual administration of peanut extract and oral administration of peanut powder can induce a 10-fold increase in tolerance as measured by food challenge. 1 1/2 years Yes
Secondary The incidence of all serious adverse events on peanut SLIT and peanut OIT. 1 1/2 years Yes
Secondary To assess any changes in clinical and mechanistic endpoints. 1 1/2 years No
Secondary Peanut tolerance, as determined by oral food challenge (OFC) after being off daily SLIT and OIT for 4 weeks. 1 1/2 years Yes
See also
  Status Clinical Trial Phase
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Enrolling by invitation NCT04885959 - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development N/A
Recruiting NCT03974555 - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Completed NCT00850668 - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults Phase 1
Withdrawn NCT00736112 - Food Allergy - Tubes - Adenoids (FATA) Trial N/A
Active, not recruiting NCT00298337 - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Phase 2/Phase 3
Completed NCT03693456 - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response N/A
Completed NCT00461097 - Oral Immunotherapy for Childhood Egg Allergy Phase 2
Completed NCT02606721 - Food Allergy Challenge Diagnostic Study
Active, not recruiting NCT02457416 - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut N/A
Completed NCT02825069 - Study on the Induction of Food Tolerance in Babies N/A
Completed NCT02350660 - Oral Immunotherapy for Peanut and Mammalian Meat Allergies N/A
Completed NCT00597675 - Oral Immunotherapy for Peanut Allergy (PMIT) Phase 2
Completed NCT00932828 - Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Phase 2
Completed NCT01373242 - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2
Completed NCT00578656 - An Interventional Study of Milk Allergy Phase 0
Completed NCT00356174 - An Observational Study of Childhood Food Allergy N/A
Completed NCT02304991 - FARE Peanut SLIT and Early Tolerance Induction Phase 2